{"id":"https://openalex.org/W7225600020","doi":"https://doi.org/10.1002/jca.70202","title":"Individualizing Apheresis Processing Volumes Using a Predictive Algorithm: Analysis of the CAR T\u2010Cell Collection Protocol Utilized in ACIT001 / EXC002 , a Phase Ib/ II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL","display_name":"Individualizing Apheresis Processing Volumes Using a Predictive Algorithm: Analysis of the CAR T\u2010Cell Collection Protocol Utilized in ACIT001 / EXC002 , a Phase Ib/ II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL","publication_year":2026,"publication_date":"2026-11-08","ids":{"openalex":"https://openalex.org/W7225600020","doi":"https://doi.org/10.1002/jca.70202","pmid":"https://pubmed.ncbi.nlm.nih.gov/43000203"},"language":"en","primary_location":{"id":"doi:10.1002/jca.70202","doi":"https://doi.org/10.1002/jca.70202","is_oa":true,"landing_page_url":"https://doi.org/10.1002/jca.70202","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jca.70202","source":{"id":"https://openalex.org/S189671064","display_name":"Journal of Clinical Apheresis","issn_l":"0733-2459","issn":["0733-2459","1098-1101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Apheresis","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jca.70202","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030984636","display_name":"Jennifer Croden","orcid":"https://orcid.org/0000-0002-2634-4341","observed_orcids":["https://orcid.org/0000-0002-2634-4341"]},"institutions":[{"id":"https://openalex.org/I154425047","display_name":"University of Alberta","ror":"https://ror.org/0160cpw27","country_code":"CA","type":"education","lineage":["https://openalex.org/I154425047"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Jennifer Croden","raw_affiliation_strings":["University of Alberta  Edmonton Canada"],"raw_orcid":"https://orcid.org/0000-0002-2634-4341","affiliations":[{"raw_affiliation_string":"University of Alberta  Edmonton Canada","institution_ids":["https://openalex.org/I154425047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034337480","display_name":"Zack M. Breckenridge","orcid":"https://orcid.org/0009-0007-9416-2615","observed_orcids":["https://orcid.org/0009-0007-9416-2615"]},"institutions":[{"id":"https://openalex.org/I168635309","display_name":"University of Calgary","ror":"https://ror.org/03yjb2x39","country_code":"CA","type":"education","lineage":["https://openalex.org/I168635309"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Zackariah Breckenridge","raw_affiliation_strings":["Riddell Centre for Cancer Immunotherapy University of Calgary  Calgary Canada"],"raw_orcid":"https://orcid.org/0009-0007-9416-2615","affiliations":[{"raw_affiliation_string":"Riddell Centre for Cancer Immunotherapy University of Calgary  Calgary Canada","institution_ids":["https://openalex.org/I168635309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030960342","display_name":"Charles Yin","orcid":"https://orcid.org/0000-0003-0322-5240","observed_orcids":["https://orcid.org/0000-0003-0322-5240"]},"institutions":[{"id":"https://openalex.org/I154425047","display_name":"University of Alberta","ror":"https://ror.org/0160cpw27","country_code":"CA","type":"education","lineage":["https://openalex.org/I154425047"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Charles Yin","raw_affiliation_strings":["University of Alberta  Edmonton Canada"],"raw_orcid":"https://orcid.org/0000-0003-0322-5240","affiliations":[{"raw_affiliation_string":"University of Alberta  Edmonton Canada","institution_ids":["https://openalex.org/I154425047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035675501","display_name":"Carina S. Debes-Marun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405258411","display_name":"Cross Cancer Institute","ror":"https://ror.org/00m3k3802","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405258411"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Carina Debes\u2010Marun","raw_affiliation_strings":["Cross Cancer Institute  Edmonton Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cross Cancer Institute  Edmonton Canada","institution_ids":["https://openalex.org/I4405258411"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027980410","display_name":"Bindu Thapa","orcid":"https://orcid.org/0000-0002-4984-2378","observed_orcids":["https://orcid.org/0000-0002-4984-2378"]},"institutions":[{"id":"https://openalex.org/I154425047","display_name":"University of Alberta","ror":"https://ror.org/0160cpw27","country_code":"CA","type":"education","lineage":["https://openalex.org/I154425047"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Bindu Thapa","raw_affiliation_strings":["University of Alberta  Edmonton Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alberta  Edmonton Canada","institution_ids":["https://openalex.org/I154425047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043785211","display_name":"Irwindeep Sandhu","orcid":"https://orcid.org/0000-0001-9407-6265","observed_orcids":["https://orcid.org/0000-0001-9407-6265"]},"institutions":[{"id":"https://openalex.org/I4405258411","display_name":"Cross Cancer Institute","ror":"https://ror.org/00m3k3802","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405258411"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Irwindeep Sandhu","raw_affiliation_strings":["Cross Cancer Institute  Edmonton Canada"],"raw_orcid":"https://orcid.org/0000-0001-9407-6265","affiliations":[{"raw_affiliation_string":"Cross Cancer Institute  Edmonton Canada","institution_ids":["https://openalex.org/I4405258411"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063797971","display_name":"Michael Patvin Chu","orcid":"https://orcid.org/0000-0002-2826-3342","observed_orcids":["https://orcid.org/0000-0002-2826-3342"]},"institutions":[{"id":"https://openalex.org/I4405258411","display_name":"Cross Cancer Institute","ror":"https://ror.org/00m3k3802","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I4405258411"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Michael P. Chu","raw_affiliation_strings":["Cross Cancer Institute  Edmonton Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cross Cancer Institute  Edmonton Canada","institution_ids":["https://openalex.org/I4405258411"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5063797971"],"corresponding_institution_ids":["https://openalex.org/I4405258411"],"apc_list":{"value":3920,"currency":"USD","value_usd":3920},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"6","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9628999829292297,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9628999829292297,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10693","display_name":"Blood transfusion and management","score":0.025599999353289604,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.9070000052452087},{"id":"https://openalex.org/keywords/blood-volume","display_name":"blood volume","score":0.6679999828338623},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.8539999723434448},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-malignancies","display_name":"relapsed/refractory B-cell malignancies","score":0.8999999761581421},{"id":"https://openalex.org/keywords/citrate-toxicity","display_name":"citrate toxicity","score":0.7960000038146973},{"id":"https://openalex.org/keywords/hypovolemia","display_name":"hypovolemia","score":0.8579999804496765},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9779999852180481},{"id":"https://openalex.org/keywords/prediction-algorithms","display_name":"predictive algorithms","score":0.5289999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8949999809265137},{"id":"https://openalex.org/C2776738589","wikidata":"https://www.wikidata.org/wiki/Q618446","display_name":"Apheresis","level":3,"score":0.6866000294685364},{"id":"https://openalex.org/C2780385302","wikidata":"https://www.wikidata.org/wiki/Q367158","display_name":"Protocol (science)","level":3,"score":0.678600013256073},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.48260000348091125},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.3840999901294708},{"id":"https://openalex.org/C37557685","wikidata":"https://www.wikidata.org/wiki/Q1896673","display_name":"Blood volume","level":2,"score":0.3716000020503998},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.3472999930381775},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.34279999136924744},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3231000006198883},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.2890999913215637},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2775000035762787},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.2770000100135803},{"id":"https://openalex.org/C134121241","wikidata":"https://www.wikidata.org/wiki/Q899301","display_name":"Yield (engineering)","level":2,"score":0.2700999975204468},{"id":"https://openalex.org/C3019252630","wikidata":"https://www.wikidata.org/wiki/Q6549547","display_name":"Limited resources","level":2,"score":0.26510000228881836},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.2549000084400177}],"mesh":[{"descriptor_ui":"D000076962","descriptor_name":"Receptors, Chimeric Antigen","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D001781","descriptor_name":"Blood Component Removal","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D001810","descriptor_name":"Blood Volume","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008228","descriptor_name":"Lymphoma, Non-Hodgkin","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D011948","descriptor_name":"Receptors, Antigen, T-Cell","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000166","qualifier_name":"cytology","is_major_topic":true},{"descriptor_ui":"D016219","descriptor_name":"Immunotherapy, Adoptive","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/jca.70202","doi":"https://doi.org/10.1002/jca.70202","is_oa":true,"landing_page_url":"https://doi.org/10.1002/jca.70202","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jca.70202","source":{"id":"https://openalex.org/S189671064","display_name":"Journal of Clinical Apheresis","issn_l":"0733-2459","issn":["0733-2459","1098-1101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Apheresis","raw_type":"journal-article"},{"id":"pmid:43000203","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/43000203","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical apheresis","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1002/jca.70202","doi":"https://doi.org/10.1002/jca.70202","is_oa":true,"landing_page_url":"https://doi.org/10.1002/jca.70202","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jca.70202","source":{"id":"https://openalex.org/S189671064","display_name":"Journal of Clinical Apheresis","issn_l":"0733-2459","issn":["0733-2459","1098-1101"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Apheresis","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225600020.pdf","grobid_xml":"https://content.openalex.org/works/W7225600020.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W1987399953","https://openalex.org/W2589755395","https://openalex.org/W2746551326","https://openalex.org/W2911241287","https://openalex.org/W2971823001","https://openalex.org/W2990150141","https://openalex.org/W3025117001","https://openalex.org/W4224305376","https://openalex.org/W4285799424","https://openalex.org/W4307706210","https://openalex.org/W4311486243","https://openalex.org/W4311502299","https://openalex.org/W4313312966","https://openalex.org/W4317738157","https://openalex.org/W4376132051","https://openalex.org/W4382727072","https://openalex.org/W4405047042","https://openalex.org/W4416785110","https://openalex.org/W7117273160","https://openalex.org/W7160896542"],"related_works":["https://openalex.org/W4417009721","https://openalex.org/W4411088947","https://openalex.org/W7117273160","https://openalex.org/W4224305376","https://openalex.org/W4372352703","https://openalex.org/W4406320487","https://openalex.org/W6929331158","https://openalex.org/W4312092931","https://openalex.org/W2978210453","https://openalex.org/W3047659610"],"abstract_inverted_index":{"Chimeric":[0],"antigen":[1],"receptor":[2],"(CAR)":[3],"T-cell":[4,32,44,94,127,181,205],"therapy":[5],"has":[6],"become":[7],"an":[8,124],"established":[9],"treatment":[10],"for":[11,96],"relapsed":[12],"or":[13,101,158],"refractory":[14],"B-cell":[15],"malignancies.":[16],"Apheresis":[17],"collection":[18,128],"of":[19,74,86,131,162,167,187],"peripheral":[20],"blood":[21,37],"mononuclear":[22],"cells":[23],"(PBMCs)":[24],"is":[25,46],"a":[26,51,108,118,135,193],"critical":[27],"first":[28],"step":[29],"in":[30,160,185],"CAR":[31,93],"manufacturing.":[33],"However,":[34],"the":[35,87,145,153,172],"total":[36],"volume":[38],"(TBV)":[39],"required":[40,169],"to":[41,48,59,65,111,139,175],"achieve":[42],"adequate":[43,157],"yield":[45,182],"difficult":[47],"predict.":[49],"As":[50,84],"result,":[52],"standard":[53,173],"practice":[54],"often":[55],"involves":[56],"processing":[57],"two":[58,174],"four":[60,176],"TBVs,":[61],"which":[62],"may":[63],"lead":[64],"unnecessary":[66,200],"time":[67],"on":[68,123],"machine":[69],"(TOM)":[70],"and":[71,82,143,148,164,211],"increased":[72],"risk":[73],"procedure-related":[75],"complications":[76],"such":[77],"as":[78],"citrate":[79],"toxicity,":[80],"hypovolemia,":[81],"thrombocytopenia.":[83],"part":[85],"ACIT001/EXC002":[88],"clinical":[89],"trial":[90],"evaluating":[91],"point-of-care":[92],"manufacturing":[95],"relapsed/refractory":[97],"non-Hodgkin":[98],"lymphoma":[99],"(NHL)":[100],"acute":[102],"lymphoblastic":[103],"leukemia":[104],"(ALL),":[105],"we":[106],"developed":[107],"pragmatic":[109],"protocol":[110,116,197],"individualize":[112],"TBV":[113,120,147,195],"processing.":[114],"This":[115],"uses":[117],"preliminary":[119,154],"estimate":[121,155],"based":[122],"assumed":[125],"CD3-positive":[126,180],"efficiency":[129],"(CE)":[130],"50%,":[132],"followed":[133],"by":[134],"midpoint":[136],"product":[137],"assessment":[138],"measure":[140],"actual":[141],"CE":[142],"adjust":[144],"remaining":[146],"TOM.":[149],"Using":[150],"this":[151],"approach,":[152],"was":[156,183],"conservative":[159],"72%":[161],"procedures,":[163],"over":[165],"75%":[166],"patients":[168],"less":[170],"than":[171],"TBVs.":[177],"The":[178],"target":[179],"achieved":[184],"93%":[186],"patients.":[188],"These":[189],"findings":[190],"demonstrate":[191],"that":[192],"midpoint-adjusted":[194],"calculation":[196],"can":[198],"minimize":[199],"TOM":[201],"while":[202],"maintaining":[203],"reliable":[204],"collection,":[206],"thereby":[207],"improving":[208],"resource":[209],"utilization":[210],"patient":[212],"safety.":[213],"TRIAL":[214],"REGISTRATION:":[215],"ClinicalTrials.gov":[216],"identifier:":[217],"NCT03938987.":[218]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-09T00:00:00"}